EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular health: an important component of cancer survivorship

Siobhan Cleary iD, Stuart D Rosen, Duncan C Gilbert, Ruth E Langley

BMJ Oncology · 2023-10 · 2 (1) · e000090

DOI: 10.1136/bmjonc-2023-000090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BMJ Oncology, online erschienen am 13.10.2023. Verfasst von Siobhan Cleary und 3 weiteren Autor:innen. Beteiligte Einrichtung: MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types. Cancer and CVD share common aetiological risk factors, for example, age, tobacco use and obesity, as well as a shared inflammatory pathogenesis. The CV risks of mediastinal radiotherapy and chemotherapy, first observed in the 1970s with anthracyclines, have long been appreciated. More recently, targeted anticancer therapeutics (human epidermal growth factor receptor-2 targeted therpies, vascular endothelial growth factor inhibitors, second/third-generation BCR-ABL inhibitors, multiple myeloma therapies and combination RAF and MEK inhibitors in particular) as well as immunotherapies have added to the burden of treatment-related CV toxicity. Additionally, cancer therapy may indirectly impact on CV health by decreasing physical activity, increasing weight gain and accelerating the ageing process. Improving overall health outcomes by considering cardiological prevention and management in cancer survivorship is an area of increasing interest. CV risk factor assessment and management are recommended post-cancer treatment in accordance with primary prevention guidelines. The European Society of Cardiology 2022 guidelines also recommend enhanced surveillance after cancer treatments with a moderate to high risk of CV consequences. The aim of this article is to provide an overview of the interconnections between cancer and CVD, review current survivorship recommendations, and highlight key areas of ongoing and future research.

Schlagwörter

Stichwörter der Autor:innen

Neoplasms

Autor:innen und Institutionen

  • MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.
  • Department of Cancer and Surgery, Imperial College Healthcare NHS Trust, London, UK.
  • National Heart and Lung Institute, Imperial College London, London, UK.

ORCID-Profile: Siobhan Cleary

Förderung

  • Medical Research Council

Zitieren

APA

Cleary, S., Rosen, S. D., Gilbert, D. C., & Langley, R. E. (2023). Cardiovascular health: an important component of cancer survivorship. BMJ Oncology, 2(1), e000090. https://doi.org/10.1136/bmjonc-2023-000090

Vancouver

Cleary S, Rosen SD, Gilbert DC, Langley RE. Cardiovascular health: an important component of cancer survivorship. BMJ Oncology. 2023;2(1):e000090. doi:10.1136/bmjonc-2023-000090

BibTeX
@article{Cleary2023,
  author = {Cleary, Siobhan and Rosen, Stuart D and Gilbert, Duncan C and Langley, Ruth E},
  title = {Cardiovascular health: an important component of cancer survivorship},
  journal = {BMJ Oncology},
  year = {2023},
  volume = {2},
  number = {1},
  pages = {e000090},
  doi = {10.1136/bmjonc-2023-000090}
}
Kostenlos starten →